FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016094100> ?p ?o ?g. }

• W2016094100 endingPage "698" @default.
• W2016094100 startingPage "692" @default.
• W2016094100 abstract "Background In 2007, sorafenib was the first drug able to improve overall survival in patients with advanced hepatocellular carcinoma. Aim In 2005 we designed a phase II study to assess safety and efficacy of sunitinib. Methods This is a single arm, open-label, single-centre phase II trial. Eligibility criteria were advanced hepatocellular carcinoma; no prior chemotherapy, performance status 0–1; and Child ≤ B8. The treatment schedule was 50 mg each day orally, 4 weeks on, 2 weeks off. Results Between 10/2007 and 10/2010, 34 patients were enrolled. A significant worsening of liver functional reserve after sunitinib was observed. Grade 3/4 adverse effects occurred in 80% of patients and included fatigue (47%), nausea (15%), liver failure (15%), encephalopathy (12%) and upper gastrointestinal bleeding (12%). Six patients (18%) died within 60 days of enrolment. A partial response was observed in 4 patients (12%). Median time to tumour progression was 2.8 months and median overall survival was 5.8 months. Conclusion A dose of 50 mg/d induces a high rate of severe adverse events. Toxicity remains a key concern also at the dose of 37.5 mg/d. However, sunitinib is able to induce a prolonged response in some patients. Positron Emission Tomography/Computed Tomography scans may select good responders." @default.
• W2016094100 created "2016-06-24" @default.
• W2016094100 creator A5000979270 @default.
• W2016094100 creator A5012446712 @default.
• W2016094100 creator A5030455428 @default.
• W2016094100 creator A5032982792 @default.
• W2016094100 creator A5033675152 @default.
• W2016094100 creator A5042241213 @default.
• W2016094100 creator A5051354035 @default.
• W2016094100 creator A5067130297 @default.
• W2016094100 creator A5076471646 @default.
• W2016094100 creator A5081498985 @default.
• W2016094100 creator A5083126449 @default.
• W2016094100 creator A5086600832 @default.
• W2016094100 date "2013-08-01" @default.
• W2016094100 modified "2023-10-03" @default.
• W2016094100 title "A phase II study of sunitinib in advanced hepatocellular carcinoma" @default.
• W2016094100 cites W1971837077 @default.
• W2016094100 cites W1981989535 @default.
• W2016094100 cites W1994193851 @default.
• W2016094100 cites W1997533142 @default.
• W2016094100 cites W2023250239 @default.
• W2016094100 cites W2029409133 @default.
• W2016094100 cites W2033373621 @default.
• W2016094100 cites W2039907242 @default.
• W2016094100 cites W2044245630 @default.
• W2016094100 cites W2073377974 @default.
• W2016094100 cites W2086889982 @default.
• W2016094100 cites W2100297634 @default.
• W2016094100 cites W2108549165 @default.
• W2016094100 cites W2109746877 @default.
• W2016094100 cites W2132206048 @default.
• W2016094100 cites W2137052325 @default.
• W2016094100 cites W2139117863 @default.
• W2016094100 cites W2139248078 @default.
• W2016094100 cites W2139511378 @default.
• W2016094100 cites W2141580755 @default.
• W2016094100 cites W2145938281 @default.
• W2016094100 cites W2147172608 @default.
• W2016094100 cites W2149456801 @default.
• W2016094100 cites W2153935627 @default.
• W2016094100 cites W2157535532 @default.
• W2016094100 cites W2158474413 @default.
• W2016094100 cites W2161558746 @default.
• W2016094100 cites W2246622039 @default.
• W2016094100 cites W2421875100 @default.
• W2016094100 doi "https://doi.org/10.1016/j.dld.2013.01.002" @default.
• W2016094100 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23410734" @default.
• W2016094100 hasPublicationYear "2013" @default.
• W2016094100 type Work @default.
• W2016094100 sameAs 2016094100 @default.
• W2016094100 citedByCount "21" @default.
• W2016094100 countsByYear W20160941002013 @default.
• W2016094100 countsByYear W20160941002014 @default.
• W2016094100 countsByYear W20160941002015 @default.
• W2016094100 countsByYear W20160941002016 @default.
• W2016094100 countsByYear W20160941002017 @default.
• W2016094100 countsByYear W20160941002018 @default.
• W2016094100 countsByYear W20160941002019 @default.
• W2016094100 countsByYear W20160941002021 @default.
• W2016094100 crossrefType "journal-article" @default.
• W2016094100 hasAuthorship W2016094100A5000979270 @default.
• W2016094100 hasAuthorship W2016094100A5012446712 @default.
• W2016094100 hasAuthorship W2016094100A5030455428 @default.
• W2016094100 hasAuthorship W2016094100A5032982792 @default.
• W2016094100 hasAuthorship W2016094100A5033675152 @default.
• W2016094100 hasAuthorship W2016094100A5042241213 @default.
• W2016094100 hasAuthorship W2016094100A5051354035 @default.
• W2016094100 hasAuthorship W2016094100A5067130297 @default.
• W2016094100 hasAuthorship W2016094100A5076471646 @default.
• W2016094100 hasAuthorship W2016094100A5081498985 @default.
• W2016094100 hasAuthorship W2016094100A5083126449 @default.
• W2016094100 hasAuthorship W2016094100A5086600832 @default.
• W2016094100 hasConcept C126322002 @default.
• W2016094100 hasConcept C141071460 @default.
• W2016094100 hasConcept C143998085 @default.
• W2016094100 hasConcept C197934379 @default.
• W2016094100 hasConcept C2777288759 @default.
• W2016094100 hasConcept C2777472916 @default.
• W2016094100 hasConcept C2778019345 @default.
• W2016094100 hasConcept C2778695046 @default.
• W2016094100 hasConcept C2779490328 @default.
• W2016094100 hasConcept C2780580376 @default.
• W2016094100 hasConcept C29730261 @default.
• W2016094100 hasConcept C31760486 @default.
• W2016094100 hasConcept C71924100 @default.
• W2016094100 hasConcept C90924648 @default.
• W2016094100 hasConceptScore W2016094100C126322002 @default.
• W2016094100 hasConceptScore W2016094100C141071460 @default.
• W2016094100 hasConceptScore W2016094100C143998085 @default.
• W2016094100 hasConceptScore W2016094100C197934379 @default.
• W2016094100 hasConceptScore W2016094100C2777288759 @default.
• W2016094100 hasConceptScore W2016094100C2777472916 @default.
• W2016094100 hasConceptScore W2016094100C2778019345 @default.
• W2016094100 hasConceptScore W2016094100C2778695046 @default.
• W2016094100 hasConceptScore W2016094100C2779490328 @default.
• W2016094100 hasConceptScore W2016094100C2780580376 @default.
• W2016094100 hasConceptScore W2016094100C29730261 @default.

• next